Brokerages expect Clearside Biomedical Inc (NASDAQ:CLSD) to post $1.44 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Clearside Biomedical’s earnings. The highest sales estimate is $4.10 million and the lowest is $80,000.00. Clearside Biomedical posted sales of $50,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 2,780%. The firm is scheduled to report its next earnings results on Wednesday, August 5th.

According to Zacks, analysts expect that Clearside Biomedical will report full year sales of $8.31 million for the current year, with estimates ranging from $4.33 million to $16.04 million. For the next year, analysts anticipate that the business will report sales of $10.86 million, with estimates ranging from $1.00 million to $30.14 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. Clearside Biomedical had a negative return on equity of 165.19% and a negative net margin of 293.61%. The business had revenue of $4.10 million during the quarter, compared to analyst estimates of $4.00 million.

CLSD has been the subject of several research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Clearside Biomedical in a research report on Tuesday, April 28th. Roth Capital started coverage on Clearside Biomedical in a report on Wednesday, May 13th. They issued a “buy” rating and a $8.00 target price for the company. ValuEngine upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, April 2nd. Wedbush reiterated a “buy” rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Thursday, June 18th. Finally, Janney Montgomery Scott reiterated a “market perform” rating and issued a $5.00 target price on shares of Clearside Biomedical in a report on Thursday, June 4th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Clearside Biomedical has a consensus rating of “Hold” and an average price target of $5.05.

In other Clearside Biomedical news, CEO George M. Lasezkay sold 32,150 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $1.99, for a total value of $63,978.50. Following the sale, the chief executive officer now directly owns 311,100 shares in the company, valued at $619,089. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.10% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of CLSD. Carmignac Gestion acquired a new stake in Clearside Biomedical in the first quarter valued at $3,367,000. Morgan Stanley acquired a new stake in Clearside Biomedical in the first quarter valued at $440,000. Oxford Asset Management LLP acquired a new stake in Clearside Biomedical in the fourth quarter valued at $382,000. Oxford Financial Group Ltd. acquired a new stake in Clearside Biomedical in the first quarter valued at $156,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Clearside Biomedical during the fourth quarter worth about $257,000. Institutional investors own 25.74% of the company’s stock.

Shares of CLSD traded down $0.05 during midday trading on Thursday, hitting $1.88. 215,841 shares of the stock were exchanged, compared to its average volume of 751,876. Clearside Biomedical has a 52-week low of $0.56 and a 52-week high of $4.13. The stock has a fifty day simple moving average of $1.99 and a 200 day simple moving average of $2.25. The firm has a market cap of $85.25 million, a P/E ratio of -4.09 and a beta of 1.07. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.71 and a current ratio of 1.71.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.

Recommended Story: What is the Consumer Price Index (CPI)?

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.